 Products  Offering an innovative personalized medicine to the marketTxCell aims to develop its proprietary autologous cell technology in order to provide physicians with innovative and personalized medication for the treatment of autoimmune and inflammatory diseases. TxCell autologous cellular therapy product candidates, have strong potential and multiple possibilities of indications.
TxCell currently has two development phase products, including one which is in clinical trials.
OvaSave®
OvaSave® is being evaluated in Phase I/IIa clinical trials for Crohn's disease.
TX-RAD
TX-RAD is being developed in preclinical studies for Rheumatoid Arthritis.
Product Pipeline
- TxCell is continuing to research possible applications of its autologous cellular therapy technology for use in new indications.
For more details on product pipeline, please click here
- TxCell has also developped a serum free, clinical grade, ex vivo cell expansion platform by using a feeder cell factory.
For more information please contact
Cet e-mail est protg contre les robots collecteurs de mails, votre navigateur doit accepter le Javascript pour le voir
|
|
